VENUSREMNSEVenus Remedies Limited· PharmaceuticalsMediumPositive
Announced Thu, 4 Jun · 16:29 IST

Venus Remedies Limited has informed the Exchange regarding 'Venus Remedies Limited Secures Renewal of Prestigious DSIR in-house R&D Recognition'.

Business Updates View source PDF

VENUSREM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+5.8%1-day move
₹1555.80
prior close
₹1593.80
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.4+1.0+2.5+2.5+5.8+3.5+4.5+10.2+15.7+19.0+24.0+5.2
Up moveDown movePending
AI summary

Venus Remedies Limited has received a renewal of its DSIR (Department of Scientific and Industrial Research) recognition for its in-house Research & Development unit. DSIR recognition is a government acknowledgment granted to industrial R&D facilities that meet certain scientific and technical standards. This renewal indicates the company continues to meet the qualifying criteria for maintaining this status. The recognition typically supports eligibility for certain tax benefits, customs duty concessions on R&D imports, and enhances the company's credibility in innovation-driven segments of the pharmaceutical industry.

Likely market impact

This is a routine regulatory renewal with no immediate material impact on revenue or earnings, though it helps the company retain tax incentives and strengthen its R&D credentials over the long term.